Rodman David Malcom 4

What Happened

• Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics (MLYS), exercised stock options to acquire 14,056 shares (paid ~$102,341 total) and sold 20,404 shares in open-market transactions for total proceeds of approximately $569,810. The exercises and sales occurred on February 12–13, 2026. The sales were executed at weighted-average prices in the $27.33–$29.64 range.

Key Details

• Transactions:
  • Feb 12, 2026: Exercised 6,349 options at $1.08 (acquired; paid ~$6,857) and sold 5,828 shares at a weighted avg $28.94 (proceeds ~$168,635) and 521 shares at $29.64 (proceeds ~$15,442).
  • Feb 13, 2026: Exercised 3,541 options at $10.20 (acquired; paid ~$36,118) and 4,166 options at $14.25 (acquired; paid ~$59,366); sold 3,541 shares at $27.33 (proceeds ~$96,776), 4,166 shares at $27.33 (proceeds ~$113,857), and 6,348 shares at $27.58 (proceeds ~$175,100).
• Total exercised (acquired): 14,056 shares (total exercise cost ≈ $102,341).
• Total sold (disposed): 20,404 shares (total proceeds ≈ $569,810).
• Footnotes:
  • F1: Sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted Oct 6, 2025.
  • F2–F4: Reported sale prices are weighted averages; shares were sold in multiple trades within the price ranges noted in the filing (details available on request).
  • F5–F6: Option vesting schedules referenced in the filing (standard multi-year vesting).
• Shares owned after the transactions: not specified in the data provided.
• Filing timeliness: Form 4 filed Feb 13, 2026 for transactions on Feb 12–13, 2026 — appears to be filed within the usual SEC timing requirements.

Context

• This was an exercise of options (derivative code M) followed by open-market sales (S). That pattern (exercise then sell) is commonly used to cover exercise costs, taxes, or to rebalance holdings and does not by itself indicate insider sentiment about the company. The presence of a 10b5-1 plan means the sales were pre-arranged under a trading plan adopted Oct 6, 2025.